Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00002480-197902500-00099 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Translation of PET radiotracers for cancer imaging: recommendations from the National Cancer Imaging Translational Accelerator (NCITA) consensus meeting.
BMC Med
January 2025
Department of Oncology, University of Oxford, Oxford, UK.
Background: The clinical translation of positron emission tomography (PET) radiotracers for cancer management presents complex challenges. We have developed consensus-based recommendations for preclinical and clinical assessment of novel and established radiotracers, applied to image different cancer types, to improve the standardisation of translational methodologies and accelerate clinical implementation.
Methods: A consensus process was developed using the RAND/UCLA Appropriateness Method (RAM) to gather insights from a multidisciplinary panel of 38 key stakeholders on the appropriateness of preclinical and clinical methodologies and stakeholder engagement for PET radiotracer translation.
Glucose Lowering through Weight management (GLoW): a randomised controlled trial of the clinical and cost effectiveness of a diabetes education and behavioural weight management programme vs a diabetes education programme in adults with a recent diagnosis of type 2 diabetes.
Diabetologia
January 2025
MRC Epidemiology Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
Aims/hypothesis: UK standard care for type 2 diabetes is structured diabetes education, with no effects on HbA, small, short-term effects on weight and low uptake. We evaluated whether remotely delivered tailored diabetes education combined with commercial behavioural weight management is cost-effective compared with current standard care in helping people with type 2 diabetes to lower their blood glucose, lose weight, achieve remission and improve cardiovascular risk factors.
Methods: We conducted a pragmatic, randomised, parallel two-group trial.
Measurement of Convexity Characteristics: A Transdisciplinary Consensus Conference.
J Wound Ostomy Continence Nurs
January 2025
Mikel Gray, PhD, RN, FNP, PNP, CUNP, CCCN, FAANP, WOCNF, FAAN , Department of Urology, University of Virginia, Charlottesville, Virginia.
While convex skin barriers have been used in patient care for decades, regulatory bodies and manufacturers have not established consistent parameters for measuring the most essential characteristics of a convex skin barrier. A transdisciplinary panel of manufacturers, engineers, marketing specialists and clinical subject matter experts from the United States was convened to address this gap. An initial consensus meeting was held to establish consensus around measurement parameters for 5 characteristics of convex skin barriers: depth, slope, flexibility, compressibility, and tension location.
View Article and Find Full Text PDFConversion Therapy for Stage IV Gastric Cancer: Report From the Expert Consensus Meeting at KINGCA WEEK 2024.
J Gastric Cancer
January 2025
Department of Surgery, Ajou University Hospital, Suwon, Korea.
Conversion therapy is a treatment strategy that shifts from palliative systemic therapy to curative surgical treatment for primary and/or metastatic stage IV gastric cancer (GC). To address its clinical statements, the Korean Gastric Cancer Association aims to present a consensus on conversion therapy among experts attending KINGCA WEEK 2024. The KINGCA Scientific Committee and Development Working Group for Korean Practice Guidelines prepared preformulated topics and 9 clinical statements for conversion therapy.
View Article and Find Full Text PDFExpert Opinion on Multiple Myeloma Treatment in Brazil in the Bispecific Antibody Era.
Clin Lymphoma Myeloma Leuk
December 2024
Universidade Federal do Rio de Janeiro -UFRJ, Rio de Janeiro, Brazil; Instituto Americas de Ensino, Pesquisa e Inovação, Rio de Janeiro, Brazil.
Multiple myeloma treatment has evolved rapidly with the development of novel targeted therapies. The paper outlines multiple myeloma epidemiology, current treatments, and recent advances, highlighting the role of bispecific antibodies. Brazilian authorities have approved 3 bispecific antibodies (teclistamab, elranatamab, and talquetamab) for relapsed/refractory multiple myeloma patients who have received at least three prior therapies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!